Scpharmaceuticals Historical Cash Flow
SCPH Stock | USD 3.28 0.14 4.09% |
Analysis of Scpharmaceuticals cash flow over time is an excellent tool to project Scpharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 755.9 K or Capital Expenditures of 28.2 K as it is a great indicator of Scpharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Scpharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Scpharmaceuticals is a good buy for the upcoming year.
Scpharmaceuticals |
About Scpharmaceuticals Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Scpharmaceuticals balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Scpharmaceuticals's non-liquid assets can be easily converted into cash.
Scpharmaceuticals Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Scpharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Scpharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Scpharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Scpharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.As of now, Scpharmaceuticals' End Period Cash Flow is increasing as compared to previous years. The Scpharmaceuticals' current Change To Liabilities is estimated to increase to about 1.7 M, while Sale Purchase Of Stock is forecasted to increase to (59 K).
Scpharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Scpharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Scpharmaceuticals cash flow statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Sale Purchase Of Stock | 4.0M | (164K) | (81K) | (54K) | (62.1K) | (59.0K) | |
Change In Cash | (805K) | 2.4M | (3.2M) | (24.4M) | (22.0M) | (20.9M) | |
Net Borrowings | (62K) | 9.6M | (2.5M) | 29.8M | 34.3M | 36.0M | |
Stock Based Compensation | 2M | 2.4M | 2.8M | 4.9M | 5.6M | 5.9M | |
Free Cash Flow | (27.7M) | (27.2M) | (34.6M) | (59.3M) | (53.4M) | (50.7M) | |
Change In Working Capital | 1.4M | (2.6M) | (350K) | (6.3M) | (5.7M) | (5.4M) | |
Begin Period Cash Flow | 72.8M | 72.0M | 74.5M | 71.2M | 81.9M | 66.3M | |
Other Cashflows From Financing Activities | (228K) | (81K) | (337K) | 812K | 730.8K | 694.3K | |
Depreciation | 399K | 438K | 468K | 626K | 719.9K | 755.9K | |
Other Non Cash Items | 639K | 678K | (695K) | (3.6M) | (3.2M) | (3.1M) | |
Total Cash From Operating Activities | (27.7M) | (27.2M) | (34.6M) | (59.2M) | (53.3M) | (50.7M) | |
Change To Operating Activities | (611K) | 236K | (234K) | (887K) | (798.3K) | (758.4K) | |
Net Income | (32.2M) | (28.0M) | (36.8M) | (54.8M) | (49.3M) | (46.9M) | |
Total Cash From Financing Activities | 60.3M | (2.5M) | 77.2M | 14.9M | 13.4M | 12.7M | |
End Period Cash Flow | 72.0M | 74.5M | 71.2M | 46.8M | 53.8M | 71.7M | |
Change To Netincome | 1.8M | 2.7M | 2.9M | 3.7M | 4.3M | 3.0M | |
Change To Liabilities | 965K | 1.2M | (2.4M) | 1.8M | 1.6M | 1.7M | |
Cash And Cash Equivalents Changes | (16.9M) | (805K) | 2.4M | (3.2M) | (3.7M) | (3.9M) | |
Cash Flows Other Operating | (609K) | 266K | (234K) | (1.8M) | (1.6M) | (1.5M) | |
Issuance Of Capital Stock | 60.6M | 1K | 47.8M | 61.8M | 71.1M | 74.6M |
Currently Active Assets on Macroaxis
BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin | |
ADA | Cardano | |
XRP | XRP |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share | Quarterly Revenue Growth 1.641 | Return On Assets | Return On Equity |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.